【摘要】 目的观察单用胰岛素样生长因子1型受体(IGF-1R)抑制剂鬼臼苦素(PPP)或联合表皮生长因子受体抑制剂厄洛替尼对卵巢上皮性癌HO-8910细胞的影响。方法使用PPP处理HO-8910细胞后,采用SRB法检测细胞的增殖情况;PI染色法检测细胞周期;Annexin-V和PI双染检测细胞凋亡;依据中效原理,使用CombiDrug软件分析PPP与厄洛替尼的协同作用。结果 PPP可抑制HO-8910细胞增殖,呈现时间剂量依赖性,其抑制作用与诱导细胞G2/M期阻滞和凋亡相关;PPP联合厄洛替尼较单用PPP或厄洛替尼能显著抑制HO-8910细胞增殖,两者联合具有协同作用。结论特异性抑制IGF-1R可以抑制卵巢癌细胞生长,诱导其凋亡;在卵巢癌的治疗中,IGF-1R和EGFR可能具有联合靶向治疗价值。更多还原

【Abstract】 Objective To investigate the effect of inhibiton of insulin-like growth factor-1 receptor(IGF-1R) and(or) epidermal growth factor receptor(EGFR) on ovarian cancer(HO-8910 cell)in vitro.Methods Cell viability was assessed by using the Sulforhodamine B(SRB) assay after the HO-8910 cell was treated with PPP.Cell cycle was analyzed by using flow cytometry(FCM) with propidium iodide(PI) labeling method.The rate of apoptosis was detected by FCM with Annexin V-FITC and PI double labeling method.Synergistic interaction on human ovarian cancer cell line HO-8910 was evaluated using the combination index(CI) method.Results PPP significantly inhibited the HO-8910 cell growth in a time-dose-dependent manner,and its inhibition role may relate to induced G2/M phase arrest and enhanced apoptosis.In addition,PPP showed a synergistic effect on HO-8910 cells with the cyto-toxicity of erlotinib.Conclusion Specific suppression of IGF-1R inhibits cell growth and induces apoptosis,and it may exert a synergistic effect with EGFR inhibitor in ovarian cancer in vitro.更多还原